Marisa Wexler, MS,  senior science writer—

A class of therapies called PDE4 inhibitors, which are approved to manage certain inflammatory diseases, may help boost the functionality of the protein whose defect causes cystic fibrosis (CF), according to a new study. Results also suggest that some available CF treatments may be effective in a broader array…

In babies with cystic fibrosis (CF), the types of bacteria living in the upper airway become more diverse during their first year of life, a new study shows. Findings suggest that clinical variables, including the use of antibiotics, had relatively minor effects on these bacterial changes in CF babies.

Images taken via an ultrasound of the liver can be used to identify children with cystic fibrosis (CF) who may be at increased risk for advanced liver disease, a new study reports. “We have demonstrated that research-based [ultrasound] screening of children with CF can identify children with a high…

Variations in levels of certain regulatory RNA molecules in immune cells may help to explain why women and girls with cystic fibrosis (CF) tend to have a higher inflammatory response than do men and boys with the disease. “We and others have reported sex-differences in the course of CF,…

30 Technology has sold the rights to its antimicrobial treatment platform for certain uses, such as for burns and acute wounds, to Convatec. 30 Technology will retain the rights to its wound care platform in other indications, including respiratory diseases such as cystic fibrosis (CF), and will be…

Women with cystic fibrosis (CF) are motivated to work with their healthcare providers to make decisions about their reproductive health, but they often are missing the necessary information and opportunities to have these discussions, a new study highlights. “Lack of information specific to people with CF about reproductive choices…

As pregnancy becomes more common among women with cystic fibrosis (CF), and more CF patients are becoming parents, there is a pressing need for CF clinics to incorporate discussions about reproductive health — with a focus on pregnant women — into routine care, a new study highlights. “As the…

Health Canada has extended its approval of Orkambi (lumacaftor/ivacaftor) to treat children as young as 1 who have cystic fibrosis (CF) caused by two copies of the F508del mutation. With this approval, about 30 children in Canada are expected to gain access to treatment that…

In a small clinical trial, Orkambi (lumacaftor/ivacaftor) appeared to reduce structural damage in the lungs, as measured by a chest MRI, for preschool-age children with cystic fibrosis (CF) who are homozygous for the F508del mutation. “This study suggests that [Orkambi] may modify CF disease progression when administered early…

Packets of molecular cargo called extracellular vesicles (EVs) can be isolated from the blood of people with cystic fibrosis (CF) and their contents may differ from those who don’t have the disease. The findings also suggest these contents in CF may be changed by CFTR modulator therapy and…